Genomics BioSci & Tech. Co.,Ltd. (TPEX:4195)
Taiwan · Delayed Price · Currency is TWD 24.70
+0.15 (0.61%)
At close: Feb 11, 2026
Genomics BioSci & Tech. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 607.89 | 482.75 | 396.14 | 419 | 389.97 | 443.18 | |
Revenue Growth (YoY) | 30.62% | 21.86% | -5.46% | 7.45% | -12.01% | 3.63% |
Cost of Revenue | 427.14 | 360.4 | 276.23 | 282.99 | 280.04 | 288.16 |
Gross Profit | 180.75 | 122.36 | 119.91 | 136.01 | 109.92 | 155.01 |
Selling, General & Admin | 190.75 | 172.71 | 148.47 | 131.79 | 121.69 | 121.8 |
Research & Development | 88.43 | 88.5 | 56.43 | 35.88 | 17.47 | 22.56 |
Operating Expenses | 284.08 | 262.65 | 201.81 | 169.53 | 138.58 | 148.42 |
Operating Income | -103.33 | -140.29 | -81.9 | -33.52 | -28.66 | 6.6 |
Interest Expense | -12.49 | -7.74 | -4.74 | -1.98 | -1.67 | -1 |
Interest & Investment Income | 2.49 | 2.37 | 2.09 | 0.35 | 0.27 | 1.17 |
Earnings From Equity Investments | 2.23 | -52.72 | -19.56 | -18.88 | -13.46 | 2.89 |
Currency Exchange Gain (Loss) | 1.5 | 0.43 | 0.86 | 0.72 | -1.31 | -2.44 |
Other Non Operating Income (Expenses) | -1.28 | 12.08 | 0.58 | 0.8 | 1.05 | 0.69 |
EBT Excluding Unusual Items | -110.88 | -185.87 | -102.67 | -52.5 | -43.78 | 7.91 |
Gain (Loss) on Sale of Investments | 0.55 | -47.06 | -65.29 | 124.76 | -9.31 | -6.98 |
Gain (Loss) on Sale of Assets | 1.83 | -1.06 | - | - | 65.18 | -4.04 |
Asset Writedown | -1.36 | -1.36 | - | - | - | - |
Other Unusual Items | 0.02 | 0 | 0.02 | - | 0.01 | 0 |
Pretax Income | -109.84 | -235.35 | -167.94 | 72.26 | 12.09 | -3.1 |
Income Tax Expense | - | - | 0.13 | 0.66 | - | -1.65 |
Earnings From Continuing Operations | -109.84 | -235.35 | -168.07 | 71.6 | 12.09 | -1.45 |
Net Income to Company | -109.84 | -235.35 | -168.07 | 71.6 | 12.09 | -1.45 |
Minority Interest in Earnings | 26.25 | 12.25 | - | - | 6.65 | 2.07 |
Net Income | -83.6 | -223.1 | -168.07 | 71.6 | 18.74 | 0.62 |
Net Income to Common | -83.6 | -223.1 | -168.07 | 71.6 | 18.74 | 0.62 |
Net Income Growth | - | - | - | 282.09% | 2927.14% | -99.27% |
Shares Outstanding (Basic) | 72 | 72 | 71 | 63 | 60 | 60 |
Shares Outstanding (Diluted) | 72 | 72 | 71 | 64 | 60 | 60 |
Shares Change (YoY) | 0.01% | 1.89% | 11.87% | 5.12% | 0.23% | -0.47% |
EPS (Basic) | -1.15 | -3.08 | -2.36 | 1.13 | 0.31 | 0.01 |
EPS (Diluted) | -1.15 | -3.08 | -2.36 | 1.13 | 0.31 | 0.01 |
EPS Growth | - | - | - | 267.48% | 3103.13% | -99.31% |
Free Cash Flow | -226.91 | -305.39 | -246.28 | -115.21 | -121.35 | -61.53 |
Free Cash Flow Per Share | -3.13 | -4.21 | -3.46 | -1.81 | -2.01 | -1.02 |
Dividend Per Share | - | - | - | 0.098 | - | - |
Gross Margin | 29.73% | 25.35% | 30.27% | 32.46% | 28.19% | 34.98% |
Operating Margin | -17.00% | -29.06% | -20.67% | -8.00% | -7.35% | 1.49% |
Profit Margin | -13.75% | -46.21% | -42.43% | 17.09% | 4.81% | 0.14% |
Free Cash Flow Margin | -37.33% | -63.26% | -62.17% | -27.50% | -31.12% | -13.88% |
EBITDA | -44.43 | -85.84 | -49.01 | -5.41 | 0.81 | 37.72 |
EBITDA Margin | -7.31% | -17.78% | -12.37% | -1.29% | 0.21% | 8.51% |
D&A For EBITDA | 58.9 | 54.45 | 32.89 | 28.1 | 29.47 | 31.12 |
EBIT | -103.33 | -140.29 | -81.9 | -33.52 | -28.66 | 6.6 |
EBIT Margin | -17.00% | -29.06% | -20.67% | -8.00% | -7.35% | 1.49% |
Effective Tax Rate | - | - | - | 0.92% | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.